Eli Lil­ly takes a one-two punch as Covid-19 an­ti­body com­bo study is halt­ed and man­u­fac­tur­ing ops fail in­spec­tion

An NIH tri­al for an Eli Lil­ly an­ti­body, one of two coro­n­avirus drugs Pres­i­dent Trump has tout­ed and urged the FDA to au­tho­rize in re­cent weeks, has been halt­ed over a safe­ty con­cern. And it is un­like­ly to start again for at least two weeks.

The study, known as AC­TIV-3, com­pared the Lil­ly an­ti­body plus remde­sivir to the an­ti­body plus place­bo in hos­pi­tal­ized Covid-19 pa­tients and was slat­ed to en­roll up to 10,000 vol­un­teers. In a state­ment re­leased late Tues­day, NI­AID said that they paused the study af­ter, in an ini­tial sam­ple of rough­ly 300 pa­tients, one group ap­peared to be do­ing bet­ter than the oth­er, al­though they did not spec­i­fy which group that was.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN